240 related articles for article (PubMed ID: 25395423)
1. Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia.
Spinler KR; Shin JW; Lambert MP; Discher DE
Blood; 2015 Jan; 125(3):525-33. PubMed ID: 25395423
[TBL] [Abstract][Full Text] [Related]
2. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
[TBL] [Abstract][Full Text] [Related]
3. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation.
Pecci A; Malara A; Badalucco S; Bozzi V; Torti M; Balduini CL; Balduini A
Thromb Haemost; 2009 Jul; 102(1):90-6. PubMed ID: 19572073
[TBL] [Abstract][Full Text] [Related]
4. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
[TBL] [Abstract][Full Text] [Related]
5. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
[TBL] [Abstract][Full Text] [Related]
6. Altered cytoskeleton organization in platelets from patients with MYH9-related disease.
Canobbio I; Noris P; Pecci A; Balduini A; Balduini CL; Torti M
J Thromb Haemost; 2005 May; 3(5):1026-35. PubMed ID: 15869600
[TBL] [Abstract][Full Text] [Related]
7. Mutations responsible for MYH9-related thrombocytopenia impair SDF-1-driven migration of megakaryoblastic cells.
Pecci A; Bozzi V; Panza E; Barozzi S; Gruppi C; Seri M; Balduini CL
Thromb Haemost; 2011 Oct; 106(4):693-704. PubMed ID: 21833445
[TBL] [Abstract][Full Text] [Related]
8. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
Zhang Y; Conti MA; Malide D; Dong F; Wang A; Shmist YA; Liu C; Zerfas P; Daniels MP; Chan CC; Kozin E; Kachar B; Kelley MJ; Kopp JB; Adelstein RS
Blood; 2012 Jan; 119(1):238-50. PubMed ID: 21908426
[TBL] [Abstract][Full Text] [Related]
9. Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.
Pecci A; Canobbio I; Balduini A; Stefanini L; Cisterna B; Marseglia C; Noris P; Savoia A; Balduini CL; Torti M
Hum Mol Genet; 2005 Nov; 14(21):3169-78. PubMed ID: 16162639
[TBL] [Abstract][Full Text] [Related]
10. Giant platelet syndromes and the MYH9 mutations.
Balduini CL
Lab Hematol; 2004; 10(3):187-8. PubMed ID: 15529446
[No Abstract] [Full Text] [Related]
11. Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA.
Kahr WH; Savoia A; Pluthero FG; Li L; Christensen H; De Rocco D; Traivaree C; Butchart SE; Curtin J; Stollar EJ; Forman-Kay JD; Blanchette VS
Thromb Haemost; 2009 Dec; 102(6):1241-50. PubMed ID: 19967157
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion.
Léon C; Eckly A; Hechler B; Aleil B; Freund M; Ravanat C; Jourdain M; Nonne C; Weber J; Tiedt R; Gratacap MP; Severin S; Cazenave JP; Lanza F; Skoda R; Gachet C
Blood; 2007 Nov; 110(9):3183-91. PubMed ID: 17664350
[TBL] [Abstract][Full Text] [Related]
13. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted MYH9 inactivation.
Eckly A; Strassel C; Freund M; Cazenave JP; Lanza F; Gachet C; Léon C
Blood; 2009 Apr; 113(14):3182-9. PubMed ID: 18984861
[TBL] [Abstract][Full Text] [Related]
14. MYH9 gene mutations associated with bleeding.
Savoia A; De Rocco D; Pecci A
Platelets; 2017 May; 28(3):312-315. PubMed ID: 28368695
[No Abstract] [Full Text] [Related]
15. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD.
Léon C; Evert K; Dombrowski F; Pertuy F; Eckly A; Laeuffer P; Gachet C; Greinacher A
Blood; 2012 Apr; 119(14):3333-41. PubMed ID: 22234693
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of
Rabbolini DJ; Chun Y; Latimer M; Kunishima S; Fixter K; Valecha B; Tan P; Chew LP; Kile BT; Burt R; Radhakrishnan K; Bird R; Ockelford P; Gabrielli S; Chen Q; Stevenson WS; Ward CM; Morel-Kopp MC
Platelets; 2018 Dec; 29(8):793-800. PubMed ID: 29090586
[No Abstract] [Full Text] [Related]
17. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in Myh9 knockout mice.
Eckly A; Rinckel JY; Laeuffer P; Cazenave JP; Lanza F; Gachet C; Léon C
J Thromb Haemost; 2010 Oct; 8(10):2243-51. PubMed ID: 20695978
[TBL] [Abstract][Full Text] [Related]
18. A novel MYH9 mutation in a patient with MYH9 disorders and platelet size-specific effect of romiplostim on macrothrombocytopenia.
Yamanouchi J; Hato T; Kunishima S; Niiya T; Nakamura H; Yasukawa M
Ann Hematol; 2015 Sep; 94(9):1599-600. PubMed ID: 26051904
[No Abstract] [Full Text] [Related]
19. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
[TBL] [Abstract][Full Text] [Related]
20. MYH9 related platelet disorders - often unknown and misdiagnosed.
Althaus K; Najm J; Greinacher A
Klin Padiatr; 2011 May; 223(3):120-5. PubMed ID: 21567368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
